Антимюллеров гормон и его прогностическая значимость для оценки качества ооцитов

Обложка

Цитировать

Полный текст

Аннотация

В статье систематизирована информация о диагностических возможностях современных клинико-лабораторных маркеров овариального резерва. Обсуждены диагностические возможности антимюллерова гормона (АМГ) в качестве маркера овариального резерва, позволяющие проводить подбор дозы гормональных препаратов и прогнозировать ответ яичника на стимуляцию в программах вспомогательных репродуктивных технологий. В работе впервые обсуждается роль АМГ в оценке качества ооцитов и последующих эмбрионов. Несмотря на недостаточные литературные данные, дальнейшее изучение АМГ, а также проведение полномасштабных исследований в данном направлении представляется крайне перспективным.

Об авторах

Наталья Владимировна Александрова

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России

Автор, ответственный за переписку.
Email: alexandrova.ncagip@gmail.com
ORCID iD: 0000-0001-7353-9515

д-р мед. наук

Россия, 117997, г. Москва, ул. акад. Опарина, 4

Список литературы

  1. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol 2017; 217: 129–40.
  2. Seifer DB, MacLaughlin DT, Christian BP et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468–71.
  3. Depmann M, Eijkemans MJ, Broer SL et al. Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis. J Clin Endocrinol Metab 2018; 103 (10): 3593–600. doi: 10.1210/jc.2018-00724
  4. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome Reproductive BioMedicine Online 2016; 33 (1): 15–28.
  5. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–1305.
  6. Rajpert-De Meyts E, Jorgensen N, Graem N et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999; 84 (10): 3836–44.
  7. Durlinger AL, Kramer P, Karels B et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789–579.
  8. Sowers M, McConnell D, Gast K et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94: 1482–6.
  9. Dewailly D, Gronier H, Poncelet E et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26 (11): 3123–9.
  10. Lin YH, Chiu WC, Wu CH et al. Anti-mullerian hormone and polycystic ovary syndrome. Fertil Steril 2011; 96 (1): 230–5.
  11. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89–100.
  12. Pacheco A, Cruz M, Iglesias C et al. Very low anti-mullerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 2018; 37: 113–9.
  13. Sunkara SK, Rittenberg V, Raine-Fenning N et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod (Oxford, England) 2011; 26: 1768–74.
  14. Sowers MR, McConnell D, Yosef M et al. Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci 2010; 1204: 95–103.
  15. Dennis NA, Houghton LA, Jones GT et al. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012; 97 (7): 2450–5.
  16. Seifer DB, Mac Laughlin D, Christian BBA et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77 (3): 468–47.
  17. Hayes E, Kushnir V, Ma X et al. Intra-cellular mechanism of anti-Mullerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol 2016; 433: 56–65.
  18. Назаренко Т.А. Эндокринные факторы женского и мужского бесплодия. Принципы гормонального лечения: монография. М., 2017. [Nazarenko T.A. Endocrine factors of female and male infertility. Principles of hormonal treatment: monograph. Moscow, 2017 (in Russian).]
  19. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
  20. Arce JC, La Marca A, Mirner Klein B et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99: 1644–53.
  21. Александрова Н.В., Марченко Л.А. Современные подходы к оценке овариального резерва у женщин с преждевременной недостаточностью яичников (обзор литературы). Проблемы репродукции. 2007; 13 (2): 22–9. [Aleksandrova N.V., Marchenko L.A. Sovremennye podkhody k otsenke ovarial’nogo rezerva u zhenshchin s prezhdevremennoi nedostatochnost’iu iaichnikov (obzor literatury). Problemy reproduktsii. 2007; 13 (2): 22–9 (in Russian).]
  22. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20: 124–40.
  23. Tarlatzi TB, Venetis CA, Devreker F et al. What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. J Assis Reprod Genet 2017; 34: 1341–51.
  24. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–30.
  25. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
  26. Melado Vidales L, Fernandez-Nistal A, Martinez Fernandez V et al. Anti-Mullerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol 2017; 69: 225–32.
  27. Yao L, Zhang W, Li H et al. The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis. Int J Clin Exp Med 2015; 8: 1755–67.
  28. Ebner T, Sommergruber M, Moser M et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod (Oxford, England) 2006; 21: 2022–6.
  29. Borges E, Braga D, Setti A et al. The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod 2017; 21: 176–82.
  30. La Marca A, Minasi MG, Sighinolfi G et al. Female age, serum antimullerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2017; 108: 777.e772–83.e772.
  31. Jiang X, Yan J, Sheng Y et al. Low anti-Mullerian hormone concentration is associated with increased risk of embryonic aneuploidy in women of advanced age. Reprod Biomed Online 2018; 37: 178–83.
  32. Fanchin R, Mendez Lozano DH, Frydman N et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 1796–802.
  33. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010; 150: 166–70.
  34. De Conto E, Genro VK, da Silva DS et al. AMH as a prognostic factor for blastocyst development. JBRA Assist Reprod 2015; 19: 131–4.
  35. Kavoussi SK, Odenwald KC, Boehnlein LM et al. Antimullerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1–4 ng/mL. Fertil Steril 2015; 104: 633–6.
  36. Lyttle Schumacher BM, Jukic AM, Steiner AZ. Anti-Mullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril 2018; 109: 1065.e1–71.e1.
  37. McCormack CD, Leemaqz SY, Furness DL et al. Anti-Mullerian hormone levels in recurrent embryonic miscarriage patients are frequently abnormal, and may affect pregnancy outcomes. J Obstet Gynaecol 2019; 39: 623–7.
  38. Tarasconi B, Tadros T, Ayoubi JM et al. Serum anti-Mullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril 2017; 108: 518–24.
  39. Gleicher N, Kushnir VA, Sen A et al. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med 2016; 14: 172.
  40. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23 (4): 411–20. doi: 10.1016/j.rbmo.2011.06.011
  41. La Marca A, Tolani AD, Capuzzo M. The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol Endocrinol 2020; 28: 1–5. doi: 10.1080/09513590.2020.1810659

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2020

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).